The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Lassa Fever Virus GP2 Protein, Mouse Fc-Tag

$593.23$2,071.58 excl. VAT

Recombinant Lassa Fever Virus GP2 protein, comprising amino acids 259-426 and incorporating a C-terminal mouse IgG2a Fc tag, produced in mammalian HEK293 human cells.

SDS-PAGE: Reducing SDS-PAGE gel showing purified Lassa fever virus Glycoprotein GP2 (Mouse Fc), showing protein migrating as a 55-60kDa band.


This Lassa fever Virus GP2 recombinant protein contains a Mouse Fc tag, and is expressed in HEK293 cells. The purified protein is designed for use in research and development of vaccines and immunodiagnostics for Lassa Fever.



  • Recombinant Lassa Virus glycoprotein 2 (GP2), corresponding to amino acids 259-426 of the Lassa virus glycoprotein precursor (NCBI P17332.1; strain GA391).
  • Expressed in mammalian cells with a C-terminal mouse IgG2a Fc-tag with a glycine-serine linker. The Fc-tag has an approximate molecular weight of 25kDa.
  • Presented in DPBS pH7.4, sterile filtered.



Lassa Fever virus is an enveloped virus with glycoprotein spikes on its surface. The Lassa Fever virus glycoprotein is synthesized as a 76-kDa glycosylated precursor protein (GP-C), which is posttranslationally cleaved into the N-terminal 44-kDa subunit GP1 and the membrane bound 36-kDa subunit Lassa Fever virus GP2. It is thought that GP2 mediates pH-dependent fusion of the viral envelope with the cellular target membrane.

Lassa fever is a severe and sometimes fatal haemorrhagic disease caused by the Lassa fever virus (LAFV). First identified in 1969 in Nigeria, LAFV is an enveloped single stranded RNA virus that belongs to the genus mammarenavirus, of the Arenaviridae family of viruses. The natural reservoir for LAFV is the Mastomys natalensis rat, and transmission of LAFV to humans is through contact with contaminated rat urine and faeces. The virus is also spread from person-to-person via contact with contaminated human excreta, blood and bodily secretions, which causes a significant risk to health workers (1). LAFV is now endemic in West Africa and a significant outbreak of Lassa fever in 2016 resulted in 160 deaths.

Most individuals infected with LAFV remain asymptomatic but severe disease may occur in 15% of cases, with 1% of cases resulting in death. Symptoms of LAFV infection are variable, and non-specific, making early diagnosis difficult. The symptoms associated with Lassa fever range from mild fever, with headaches and fatigue, to severe life threatening multi organ failure. Early stages of the disease resemble symptoms of typhoid and malaria and therefore misdiagnosis is a risk (WHO, 2017).



Certificate of analysis
Safety Datasheet